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Mutations causing amyotrophic lateral sclerosis (ALS) clearly implicate ubiquitously expressed and predominantly nuclear RNA
binding proteins, which form pathological cytoplasmic inclusions in this context. However, the possibility that wild-type RNA
binding proteins mislocalize without necessarily becoming constituents of cytoplasmic inclusions themselves remains relatively
unexplored. We hypothesized that nuclear-to-cytoplasmic mislocalization of the RNA binding protein fused in sarcoma (FUS),
in an unaggregated state, may occur more widely in ALS than previously recognized. To address this hypothesis, we analysed
motor neurons from a human ALS induced-pluripotent stem cell model caused by the VCP mutation. Additionally, we examined
mouse transgenic models and post-mortem tissue from human sporadic ALS cases. We report nuclear-to-cytoplasmic mislocaliza-
tion of FUS in both VCP-mutation related ALS and, crucially, in sporadic ALS spinal cord tissue from multiple cases. Furthermore,
we provide evidence that FUS protein binds to an aberrantly retained intron within the SFPQ transcript, which is exported from
the nucleus into the cytoplasm. Collectively, these data support a model for ALS pathogenesis whereby aberrant intron retention in
SFPQ transcripts contributes to FUS mislocalization through their direct interaction and nuclear export. In summary, we report
widespread mislocalization of the FUS protein in ALS and propose a putative underlying mechanism for this process.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a relentlessly progres-
sive neurodegenerative condition, which remains incurable
due to our incomplete understanding of the molecular
pathogenesis. Genetic discoveries in ALS strongly implicate
ubiquitously expressed regulators of RNA-processing
(Taylor et al., 2016). Pathologically, in 97% of cases,
TDP-43 protein is mislocalized from the nucleus to the
cytoplasm, where it aggregates (Neumann et al., 2006).
However, ALS-causing mutations in fused in sarcoma
(FUS) and superoxide dismutase 1 (SOD1) conspicuously
lack TDP-43 proteinopathy in the majority of cases
(Mackenzie et al., 2007). FUS aggregation is a recognized
feature of FUS mutation-related ALS (Vance et al., 2009).
However, the concept that wild-type FUS nuclear-to-cyto-
plasmic mislocalization (rather than aggregation) might be
a more widespread feature of other forms of ALS has not
been systematically assessed to our knowledge. Indeed such
mislocalization may have evaded detection thus far due to
bias towards studying aggregates/inclusions rather than
perturbed subcellular localization of unaggregated proteins
alone. This possibility is strengthened by the facts that (i)
impaired nuclear-cytoplasmic compartmentalization is in-
creasingly recognized as a key feature of ALS (Boeynaems
et al., 2016); and (ii) FUS is known to shuttle between the
nucleus and cytoplasm.
Here we systematically investigated FUS protein localiza-
tion across a human induced pluripotent stem cell (iPSC)
model, mouse transgenic models and human post-mortem
tissue from multiple cases of sporadic ALS. We ﬁnd that
the nuclear-to-cytoplasmic mislocalization of FUS is a more
widespread feature of ALS than previously recognized.
Furthermore, we present evidence that supports a putative
molecular mechanism for this mislocalization through inter-
action between FUS protein and the aberrant intron-retain-
ing SFPQ transcript.
Materials and methods
Induced pluripotent stem cell culture
and motor neuron differentiation
IPSCs were maintained using standard protocols. Motor
neuron differentiation was carried out as described previously
(Hall et al., 2017; Luisier et al., 2018). See Supplementary
material for more detailed information. Details of iPSC lines
are provided in Supplementary Table 1.
Animals, transgenic models and
tissue processing
All experiments were carried out following the guidelines of
the UCL Institute of Neurology Genetic Manipulation and
Ethic Committees and in accordance with the European
Community Council Directive of November 24, 1986 (86/
609/EEC). Animal experiments were undertaken under licence
from the UK Home Ofﬁce in accordance with the Animals
(Scientiﬁc Procedures) Act 1986 (Amended Regulations 2012)
and were approved by the Ethical Review Panel of the Institute
of Neurology. The following transgenic mouse lines were used,
and were analysed as different experimental groups: (i) female
SOD1G93A mice [B6SJL-Tg(SOD1*G93A)1Gur/J, Jackson
Laboratories], postnatal Day 93–95 (P93–95) (n = 4 mice);
(ii) male over-expressing mutant human VCPA232E were gen-
erated by J. Paul Taylor et al., St Jude Children’s Research
Hospital, Memphis, TN, USA and are described in Custer
et al. (2010) and bred to wild-type C57 Black 6 (C57/B6)
background, symptomatic, 9 months old (n = 3 mice); and
(iii) wild-type C56BL/6-SJL mixed background (Jackson
Laboratories) were used as control (n = 4 mice). Mice were
bred and maintained at the UCL Institute of Neurology in
standard individually ventilated cages with up to three mice
per cage, in a temperature and humidity controlled environ-
ment with a 12-h light/dark cycle and had access to drinking
water and food ad libitum. Cages were checked daily to ensure
animal welfare. Body weight was assessed regularly to ensure
no weight loss. For tissue collection, animals were injected
with terminal anaesthesia (pentobarbital sodium, Euthatal)
and were transcardially perfused with 4% paraformaldehyde.
The lumbar region of the spinal cord was removed and post-
ﬁxed with 4% paraformaldehyde and cryoprotected overnight
with 30% sucrose; 10 or 20 mm serial transverse cryosections
were cut for immunoﬂuorescence staining.
Human post-mortem tissue
Snap frozen tissue sections were obtained from lumbar spinal
cords of eight healthy donors and 12 age and sex matched
sporadic ALS patients (Supplementary Table 2). Death to
snap-freezing delay times were also comparable between the
groups [mean delay  standard deviation (SD): 30.13  12.87
and 27.75  10.63 h, for control and sporadic ALS patients,
respectively]. The spinal cord samples were obtained from the
tissue bank NeuroResource, UCL Institute of Neurology,
London, UK. Samples were donated to the tissue bank with
written tissue donor informed consent following ethical review
by the NHS NRES Committee London–Central and stored
under a Research Sector Licence from the UK Human Tissue
Authority (HTA). In this study, ALS cases were considered
sporadic by the absence of any family history of motor
neuron disease. Furthermore, all cases showed TDP-43 path-
ology when screened by NeuroResource, suggesting that they
are not SOD1 mutants [as TDP-43 pathology is absent in
SOD1-related ALS cases (Mackenzie et al., 2007)].
Immunolabelling, imaging and image
analysis
For immunocytochemistry and immunohistochemistry, samples
were blocked in 10% normal goat serum (NGS) or 10%
normal donkey serum (NDS) as appropriate and permeabilized
in 0.3% TritonTM X-100 [Sigma-Aldrich; in phosphate-buf-
fered saline (PBS)] at room temperature for 1 h.
Immunolabelling was performed with primary antibodies in
NGS (5%) and TritonTM X-100 (0.1% in PBS) at 4C over-
night followed by species-speciﬁc secondary antibodies for 1 h
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at room temperature and DAPI nuclear counterstain (100 ng/
ml) for 10min at room temperature. For human post-mortem
samples ﬁxation and permeabilization in cold methanol
(20C, 20min) was performed before the immunostaining.
Primary antibodies were diluted as follows: goat anti ChAT
(Millipore, AB144P) 1:100; rabbit and mouse anti FUS
(Abcam, ab84078 1:500; and Santa Cruz, sc-47711 1:100 re-
spectively). Images were acquired using either a 710 Laser
Scanning Confocal Microscope (Zeiss) or the Opera Phenix
High-Content Screening System (Perkin Elmer). Images were
acquired as confocal z-stacks with a z-step of 1 mm and pro-
cessed to obtain a maximum intensity projection. For the ana-
lysis of nuclear/cytoplasmic ratio of FUS in iPSC-derived cells,
images were analysed using the Columbus Image Analysis
System (Perkin Elmer). The animal and post-mortem tissue
sections were analysed using Fiji. Motor neurons were identi-
ﬁed by choline acetyltransferase (ChAT) immunoreactivity,
and the nuclear and cytoplasmic area were manually drawn
based on DAPI and ChAT staining, respectively. For each cell,
the average FUS immunoreactivity intensity in each region of
interest was measured, background was subtracted, and the
ratio between nuclear and cytoplasmic average intensity was
calculated and used as the main experimental outcome.
Cell fractionation, RNA extraction,
reverse transcription and
quantitative PCR
For the biochemical fractionation of iPSC-derived neural pre-
cursors the Ambion PARIS kit (Thermo Fisher Scientiﬁc) was
used following manufacturer’s instructions. A cytosolic frac-
tion was obtained by lysing the cultures for 10min in ice-
cold cell fractionation buffer. Nuclei were lysed in 8M Urea
Nuclear Lysis Buffer, containing 50mM Tris-HCl (pH 8),
100mM NaCl, 0.1% SDS, 1mM DTT. Both lysis buffer con-
tained 0.1 U/ml RiboLock RNase Inhibitor (Thermo Fisher
Scientiﬁc). RNA was extracted from both fractions using the
Promega Maxwell RSC simplyRNA cells kit including DNase
treatment, alongside the Maxwell RSC instrument. Reverse
transcription was performed using the RevertAidTM First
Strand cDNA Synthesis Kit (Thermo Fisher Scientiﬁc) using
1 mg of RNA and random hexamers. Quantitative PCR was
performed using the PowerUPTM SYBR Green Master Mix
(Thermo Fisher Scientiﬁc) and the the QuantStudioTM 6 Flex
Real-Time PCR System (Applied Biosystems). Speciﬁc ampliﬁ-
cation was determined by melt curve analysis and agarose gel
electrophoresis of the PCR products. Analysis of intron retain-
ing transcripts was performed as previously described (Luisier
et al., 2018). Levels of intron retention (primer pair F2R2)
were normalized over the expression level of each individual
gene (primer pair F1R1). Primers used were as follows: SFPQ
F1: GCCGAATGGGCTACATGGAT; SFPQ R1: TCAGTACG
CATGTCACTTCCC; SFPQ F2: GTGGATCGACTCATTGGT
GA; SFPQ R2: TTCCTCTAGGACCCTGTCCA.
Single molecule fluorescence in situ
hybridization
Based on Raj et al. (2008), iPSC-derived neural precursors
(Day 7 after beginning of neural conversion) that were
grown on Geltrex-coated sterile 2-well m-Slides (80286,
Ibidi) were washed twice for 5min with PBS, and ﬁxed using
4% methanol-free formaldehyde (10321714, Thermo Fisher
Scientiﬁc) for 10min at room temperature. Following add-
itional two wash steps, cells were permeabilized using 70%
ethanol for 12 h at 4C, and were washed twice again. Then
preparations were incubated for 15min with hybridization
buffer prepared using 2 saline-sodium citrate (SSC) solu-
tion/10% deionized formamide (4610-OP, Calbiochem).
Hybridization with Stellaris FISH probes was done in a total
volume of 50 ml hybridization buffer containing 50 mg competi-
tor tRNA from Escherichia coli (10109541001, Roche
Diagnostics), 10% dextran sulphate (9011–18–1, VWR),
2mg/ml UltraPure BSA (AM2616, Thermo Fisher Scientiﬁc),
and 10mM vanadyl-ribonucleoside complex (S1402S,
New England Biolabs) with probes at ﬁnal concentration of
1 ng/ml. Preparations were covered with paraﬁlm and incu-
bated at 37C for 5 h, and afterwards washed twice with
pre-warmed 2  SCC/10% formamide for 30min at 37C.
Finally the preparations were washed twice with PBS at
room temperature, and then mounted using 10 ml ProLong
Gold Antifade Reagent containing DAPI (9071S, New
England Biolabs). The slides were imaged when the mounting
medium was fully cured 412 h.
Probes were designed using the Probe Designer software from
Biosearch Technologies and were provided by same vendor.
Probes included were designed against SFPQ intron conjugated
to Quasar570 (SMF-2037–1) and mature SFPQ conjugated to
Quasar670 (sequences of probes available upon request).
Quantiﬁcation of hybridization signal was performed using
custom spot-intensity detection algorithm in DAPI segmented
cells to separate nuclear and cytoplasmic signal.
Data analysis of FUS protein
subcellular localization
We used R and lme4 (Bates et al., 2015) to perform linear
mixed effects analysis of the relationship between FUS local-
ization and VCP or SOD1 mutation, as well as with sporadic
ALS, that accounts for idiosyncratic variation due to either
animal or individual differences. As ﬁxed effects, we either
entered the mutation or the ALS disease variable into the
model. As random effects, we had intercepts for either animals
(SOD1, VCP) or patients and batches. Visual inspection of
residual plots did not reveal any obvious deviations from
homoscedasticity or normality. P-values were obtained by like-
lihood ratio tests of the full model with the effect in question
against the model without the effect in question.
Mapping of iCLIP data
Raw FUS individual-nucleotide resolution cross-linking and
immunoprecipitation (iCLIP) data can be accessed at https://
imaps.genialis.com/ (Attig et al., 2018). Before alignment, two-
stage adapter removal was performed using Cutadapt accord-
ing to the ENCODE iCLIP standard operating procedure. A
two-stage approach was also used for alignment. First,
Bowtie2 was used to remove reads aligning to rRNA or
tRNA. Then, STAR was used to align the remaining reads
to GRCh38, with only uniquely mapping reads retained.
PCR duplicates were collapsed based on the unique molecular
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identiﬁers and mapping locations. The nucleotide-resolution
crosslink position was calculated as the coordinate immedi-
ately preceding the reverse transcription truncation event.
Compliance with ethical standards
For human iPSC work, informed consent was obtained from
all patients and healthy controls in this study. Experimental
protocols were all carried out according to approved regula-
tions and guidelines by UCLH’s National Hospital for
Neurology and Neurosurgery and UCL Queen Square
Institute of Neurology joint research ethics committee (09/
0272). The human post-mortem spinal cord samples were ob-
tained from the tissue bank NeuroResource, UCL Queen
Square Institute of Neurology, London, UK. Samples were
donated to the tissue bank with written tissue donor informed
consent following ethical review by the NHS NRES Committee
London–Central and stored under a Research Sector Licence
from the UK Human Tissue Authority (HTA). All animal ex-
periments described in this study were carried out under li-
cence from the UK Home Ofﬁce, and were approved by the
Ethical Review Panel of the Institute of Neurology.
Data availability
Data supporting the ﬁndings of this study are available from
the corresponding author, upon reasonable request.
Results
Nuclear-to-cytoplasmic
mislocalization of FUS in human and
mouse VCP-mutant ALS models
Previously, we reported robust differentiation of human
iPSCs into highly enriched (485%) cultures of comprehen-
sively validated and functionally characterized spinal cord
motor neurons (Hall et al., 2017; Mafﬁoletti et al., 2018).
Using this approach, we have found clear molecular patho-
genic phenotypes in a human iPSC model of VCP-related
ALS (four clones from two patients with the mutations
VCPR155C and VCPR191Q) (Hall et al., 2017; Luisier et al.,
2018). We harnessed this well-characterized ALS model to
investigate the subcellular localization of FUS protein, which
revealed a modest but statistically signiﬁcant (P50.001)
decrease in nuclear-to-cytoplasmic localization during
motor neuron differentiation (Fig. 1A). We next sought to
validate this ﬁnding in vivo by examining tissue sections
from symptomatic transgenic VCPA232E mice. Additionally,
we examined tissue from the SOD1G93A mouse model as a
comparator. Using linear mixed model analysis that ac-
counts for inter-animal variation we showed that although
FUS remained within the nucleus in the SOD1 mouse model
[2(1) = 0.031, P = 0.955], nuclear-to-cytoplasmic mislocaliza-
tion abounded in the VCP mouse model, with a reduction in
FUS nuclear to cytoplasmic ratio of 4.0176  1.1775
[2(1) = 8.164, P = 0.0042] (Fig. 1B).
Nuclear-to-cytoplasmic
mislocalization of FUS in human
sporadic ALS
Having established that FUS is mislocalized in VCP-related
ALS models, but not in SOD1, we next sought to address
the generalizability of this ﬁnding across sporadic forms of
ALS (which represent 90% of all cases). To this end, we
examined post-mortem spinal cord tissue from 12 sporadic
ALS cases and eight healthy controls (Fig. 2A). We found
clear evidence of nuclear-to-cytoplasmic FUS mislocaliza-
tion in these sporadic ALS cases, but in the absence of
cytoplasmic FUS inclusions.
A reduction in motor neuronal soma size has been pre-
viously shown in an in vitro model of ALS which associates
with increased apoptosis (Kiskinis et al., 2014). We thus
investigated whether changes in FUS subcellular localiza-
tion in sporadic ALS samples accompany alterations in
cell morphology. Using single-cell analysis of nuclear and
cell size, we demonstrated signiﬁcant reductions in both
nuclear and cytoplasmic areas in sporadic ALS versus con-
trol motor neurons (Fig. 2B), which did not correlate with
reduction in FUS nuclear-to-cytoplasmic localization in
sALS cases (Fig. 2C).
FUS binds to an aberrantly retained
intron within the SFPQ transcript,
which is exported from the nucleus
Having found clear evidence that FUS nuclear-to-cytoplas-
mic mislocalization is more widespread in ALS than pre-
viously recognized, we sought to understand its molecular
interplay with 167 aberrant intron retaining transcripts
that we recently described in ALS (Luisier et al., 2018).
To this end we analysed iCLIP data, which allowed iden-
tiﬁcation of RNA binding targets of the FUS protein.
Using this approach, we found that FUS protein binds
extensively to the aberrantly retained intron 9 within the
SFPQ transcript (Fig. 3A and B), which we identiﬁed as
the most signiﬁcantly retained intron across diverse ALS
mutations (Luisier et al., 2018). We next conﬁrmed that
the SFPQ intron-retaining transcript is exported to the
cytoplasm using nuclear-cytoplasmic cellular fractionation
and qPCR (Fig. 3C), showing an increased proportion of
SFPQ intron retaining transcript in the cytosol of VCP
mutant cultures. We used single molecule RNA ﬂuores-
cence in situ hybridization (smFISH) as orthogonal valid-
ation that this transcript is exported from the nucleus
(Fig. 3D).
Discussion
The core ﬁnding of our study is that the FUS protein is
mislocalized from the nucleus to the cytoplasm in cases
beyond FUS mutation-related ALS. Speciﬁcally, we ﬁnd
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FUS mislocalization in VCP mutation-related ALS and, cru-
cially, in sporadic ALS. Our ﬁndings have been carefully
cross-validated in iPSC lines (four VCP mutant and four
control iPSC lines), a mouse transgenic model (three VCP
mutant and three control mice), and post-mortem tissue (12
sporadic ALS cases and eight control cases). The pervasive
mislocalization of FUS has likely evaded detection thus far
as FUS largely remains unaggregated in the cytoplasm,
rather than forming part of the TDP-43 aggregates in spor-
adic ALS cases.
Figure 1 Nuclear-to-cytoplasmic mislocalization of FUS in human and mouse VCP-mutant ALS models. (A) Subcellular local-
ization of FUS determined by immunocytochemistry in iPSCs (D0), neural precursors (NPCs; D7) and patterned motor neuron precursors
(pMNs; D14). The ratio of the average intensity of the FUS immunolabelling in the nucleus (N) versus cytoplasm (C) was automatically determined
in both CTRL and VCP mutant lines cells. Data shown are average N/C ratios (SD) per field of view from four control and four VCP mutant
lines. P-value from unpaired t-test with Welch’s correction. (B) Analysis of the subcellular localization of FUS in motor neurons in the ventral
spinal cord of wild-type, VCPA232E and SOD1G93A mice. Motor neuron cytoplasm was identified by ChAT staining, nuclei were counterstained with
DAPI. Images were acquired as confocal z-stacks using a Zeiss 710 confocal microscope with a z-step of 1mm, processed to obtain a maximum
intensity projection and analysed using Fiji. Motor neurons were identified by ChAT staining, and the nuclear and cytoplasmic area were manually
drawn based on DAPI and ChAT staining respectively. For each region of interest, the average FUS immunoreactivity intensity was measured,
background was subtracted, and the ratio between nuclear and cytoplasmic average intensity was calculated. Data shown are nuclear/cytoplasmic
(N/C) ratio (mean  SD) per cell from four wild-type, four SOD1G93A and three VCPA232E mice. Scale bar = 20 mm. Linear mixed effects analysis of
the relationship between FUS localization and either VCP or SOD1 mutation to account for idiosyncratic variation due to animal differences:
SOD1 mutation does not affect FUS localization [2(1) = 0.6387, P = 0.4242], lowering it by about 0.8152  1.1152 (standard errors), while VCP
mutation does affect FUS localization [2(1) = 8.3145, P = 0.003933], lowering it by 4.2175  0.9731 (standard errors).
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Our ﬁndings support a model whereby FUS mislocaliza-
tion from the nucleus to the cytoplasm occurs in the ma-
jority of ALS cases, but it generally does not appear to
aggregate in the cytoplasm. Nuclear loss of FUS protein
may impair pre-mRNA splicing whilst the possibility of a
cytosolic toxic gain of function is also noteworthy in light
of recent studies (Lo´pez-Erauskin et al., 2018).
Interestingly, TDP-43 aggregation is also observed in
most familial and sporadic ALS cases, except from those
caused by SOD1 mutations. Thus, FUS mislocalization
appears to occur in a similar majority of cases to TDP-
43 aggregation. Importantly, the mislocalized FUS is
Figure 2 Nuclear-to-cytoplasmic mislocalization of FUS in human sporadic ALS. (A) Analysis of the subcellular localization of FUS in
motor neurons in the ventral spinal cord of healthy controls (n = 8) and patients with sporadic ALS (sALS) (n = 12). Motor neuron cytoplasm was
identified by ChAT immunolabelling, nuclei were counterstained with DAPI. N/C ratio of FUS immunoreactivity was measured as described in Fig.
1B. Only motor neurons with a visible nucleus were considered for the analysis. We used R and lme4 (Bates et al., 2015) to perform a linear mixed
effects analysis of the relationship between FUS localization and sALS disease. Scale bar = 20mm. Data shown is N/C ratio (mean  SD) per cell
from at least eight cases per group. (B) Nuclear and cytoplasmic areas of motor neuron nuclei and cytoplasm in sALS (n = 12) versus control
(n = 8). Data shown is mean  SD. P-values from non-parametric Mann-Whitney’s test. (C) Single-cell measurement of nuclear (right) and
cytoplasmic area (left) shows no correlation with FUS nuclear to cytoplasmic ratio as shown with scatter plots. PCC = Pearson correlation
coefficient.
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Figure 3 FUS binds to an aberrantly retained intron within the SFPQ transcript, which is exported from the nucleus. (A) Bar
plots depicting the level of enrichment in FUS-binding to the retained intron compared with non-retained introns within the same gene. Analysis of
the 167 previously reported as aberrantly retained introns in ALS. (B) Genome browser view of FUS iCLIP crosslinking events along the SFPQ and
FUS transcript. Grey boxes highlight the location of retained introns. (C) Dot plot showing the levels of cytoplasmic intron retention (IR) SFPQ
transcripts measured by qPCR. IR transcript levels were measured using an IR-specific primer pair and normalized over the expression levels of a
constitutive SFPQ exon, as described previously (Luisier et al., 2018). n = 5 control lines and n = 4 VCP lines, mean  standard error of the mean
(SEM) from two independent replicates per line, each analysed in technical duplicate. P = 0.0041 from Welch’s test. [D(i)] Single molecule
fluorescence in situ hybridization (smFISH) showing SFPQ intron-retaining transcript in the cytoplasm. The top panel shows the nuclear staining
only for context; the probe clearly detects intron-retaining transcripts in the cytoplasm. [D(ii)] Quantification and statistical analysis of smFISH
performed on three control lines and three VCP mutant lines using Welch’s test. (E) Schematic diagram of proposed model. Cartoon summarizing
the functional consequence of aberrant IR in SFPQ transcript. The 9 kb intron 9 in SFPQ is retained and exported to the cytoplasm. The FUS
protein binds extensively to this retained intron. The FUS protein itself is abundantly relocalized from the nucleus to the cytoplasm in diverse ALS
models (human iPSC and mouse transgenic), as well as post-mortem samples from patients with sporadic ALS.
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observed in mouse and iPSC models at early stages,
before the onset of TDP-43 aggregates, indicating
that the mislocalized unaggregated FUS might play a
causative role early in the ALS disease process, perhaps
by creating a more aggregation-prone cytoplasmic
environment.
Our analysis of iCLIP data suggest that FUS binds avidly
to the aberrantly retained intron of the SFPQ transcript in
ALS. Cumulatively, our data are consistent with a working
hypothesis that wild-type FUS might travel out of the nu-
cleus when bound to the aberrantly retained intron 9 of the
SFPQ transcript in ALS (Fig. 3E), though conﬁrmation of
such a mechanism will require detailed molecular follow-up
work.
In our previous study, we showed SFPQ intron retention
occurs in VCP, SOD1 and FUS mutant iPSC-motor neuron
cultures and that this correlates with loss of nuclear SFPQ
across different model systems (Luisier et al., 2018). The
current study, however, adds interesting complexity to this
paradigm by suggesting that RNA-binding proteins seques-
tered by the SFPQ intron-retaining transcript might vary in
a mutation-dependent manner. Indeed although SFPQ pro-
tein is sequestered by the SFPQ intron-retaining transcript
across different mutations we examined, FUS is not statis-
tically signiﬁcantly sequestered and/or exported from the
nucleus by this transcript in the context of SOD1 muta-
tions. In addition to the evidence we provided in our pre-
vious work (Luisier et al., 2018), mutant SOD1 has also
been shown to bind RNA transcripts in other contexts,
playing a role in their stabilization (Chen et al., 2014; Lu
et al., 2007, 2009). Furthermore, SOD1 is known to form
complexes with other ribonucleoproteins such as TIAR and
HuR (Lu et al., 2007, 2009). To further support the con-
cept that mutant SOD1 can inﬂuence the localization (and
therefore function) of other RNA binding proteins, a recent
proteomic study found a nuclear shift in proteins involved
in RNA transport and processing in SOD1 mutants com-
pared to controls (Kim et al., 2017). In aggregate, these
studies raise the hypothesis that by altering RNA metabol-
ism, mutations in SOD1 could lead to mutation-dependent
changes in the molecular composition of ribonucleoprotein
complexes. Speciﬁcally, mutant SOD1 might affect the
interaction of speciﬁc RNA binding proteins, such as
FUS, with their target RNAs. The absence of FUS misloca-
lization in this context, together with the lack of TDP-43
proteinopathy, seems to further substantiate a recognized
pathological divergence between SOD1-ALS and other
forms of familial and sporadic ALS.
In summary, we report a previously unrecognized wide-
spread mislocalization (but not aggregation) of FUS in
ALS, and propose a putative context-speciﬁc mechanism
for this through its interaction with the ALS-related ab-
errantly retained intron 9 in SFPQ transcripts. These ﬁnd-
ings raise the prospect of targeting the nuclear-to-
cytoplasmic mislocalization of unaggregated FUS as a pu-
tative therapeutic strategy in ALS.
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